Advertisement

Infection

, Volume 39, Issue 4, pp 333–340 | Cite as

Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy

  • S. Meier
  • R. Weber
  • R. Zbinden
  • C. Ruef
  • B. HasseEmail author
Clinical and Epidemiological Study

Abstract

Background

Extended-spectrum β-lactamases (ESBLs) are an increasing challenge in the treatment of urinary tract infections (UTIs), and also in the community. We aimed to investigate the characteristics of patients with UTIs due to ESBL-producing Escherichia coli and to assess the risk factors for ESBLs in community-acquired isolates.

Methods

We performed a retrospective study from January 1, 2007 to December 31, 2009 at a tertiary care teaching hospital in Switzerland, comparing patients with community-acquired versus healthcare-associated UTIs due to ESBL-producing E. coli. Additionally, we investigated the antimicrobial susceptibility of these isolates.

Results

A total of 123 patients were studied, of whom 79 (64%) had community-acquired and 44 (36%) had healthcare-associated UTIs. Community-acquired isolates were associated with acute uncomplicated UTIs (odds ratio [OR] 6.62, 95% confidence interval [CI] 1.83–36.5, P < 0.001). Risk factors were recurrent UTI (OR 3.04, 95% CI 1.14–9.14, P = 0.022) and female sex (OR 2.46, 95% CI 1.01–6.08). Community-acquired ESBL-producing E. coli urinary isolates showed high resistance rates to most of the currently used oral antimicrobial agents, including β-lactam antibiotics (amoxicillin–clavulanic acid, 69.6% resistance), quinolones (ciprofloxacin, 84.8% resistance; norfloxacin, 83.9% resistance), and trimethoprim–sulfamethoxazole (75.9% resistance), except for nitrofurantoin (15% resistance) and fosfomycin (0% resistance).

Conclusion

UTI due to ESBL-producing E. coli are emerging, and also in a country with low antibiotic use. Because of increasing antibiotic resistance rates of E. coli to current standard therapy and because of the resistance patterns of ESBL-producing E. coli, guidelines for the management of UTIs must be revised. Fosfomycin or nitrofurantoin are recommended for the first-line empirical oral treatment of community-acquired uncomplicated UTIs.

Keywords

Community-acquired urinary tract infection Extended-spectrum β-lactamases (ESBLs) Nitrofurantoin Fosfomycin 

Notes

Conflict of interest

All authors have no conflicts of interest to declare.

References

  1. 1.
    Nicoletti J, Kuster SP, Sulser T, et al. Risk factors for urinary tract infections due to ciprofloxacin-resistant Escherichia coli in a tertiary care urology department in Switzerland. Swiss Med Wkly. 2010;140:w13059.PubMedGoogle Scholar
  2. 2.
    Arslan H, Azap OK, Ergönül O, et al. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother. 2005;56:914–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Oteo J, Pérez-Vázquez M, Campos J. Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis. 2010;23:320–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159–66.PubMedCrossRefGoogle Scholar
  5. 5.
    Yamamoto S, Higuchi Y, Nojima M. Current therapy of acute uncomplicated cystitis. Int J Urol. 2010;17:450–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Auer S, Wojna A, Hell M. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother. 2010;54:4006–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Livermore DM. Defining an extended-spectrum beta-lactamase. Clin Microbiol Infect. 2008;14:3–10.PubMedCrossRefGoogle Scholar
  8. 8.
    Rodríguez-Baño J, Navarro MD, Romero L, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol. 2004;42:1089–94.PubMedCrossRefGoogle Scholar
  9. 9.
    Rodríguez-Baño J, Alcalá JC, Cisneros JM, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med. 2008;168:1897–902.PubMedCrossRefGoogle Scholar
  10. 10.
    Laupland KB, Church DL, Vidakovich J, et al. Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect. 2008;57:441–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Calbo E, Romaní V, Xercavins M, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother. 2006;57:780–3.PubMedCrossRefGoogle Scholar
  12. 12.
    Colodner R, Rock W, Chazan B, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis. 2004;23:163–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Azap OK, Arslan H, Serefhanoğlu K, et al. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect. 2010;16:147–51.PubMedCrossRefGoogle Scholar
  14. 14.
    Ben-Ami R, Rodríguez-Baño J, Arslan H, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis. 2009;49:682–90.PubMedCrossRefGoogle Scholar
  15. 15.
    Yilmaz E, Akalin H, Ozbey S, et al. Risk factors in community-acquired/onset urinary tract infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Chemother. 2008;20:581–5.PubMedGoogle Scholar
  16. 16.
    Kuster SP, Hasse B, Huebner V, et al. Risks factors for infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care university hospital in Switzerland. Infection. 2010;38:33–40.PubMedCrossRefGoogle Scholar
  17. 17.
    Friedmann R, Raveh D, Zartzer E, et al. Prospective evaluation of colonization with extended-spectrum beta-lactamase (ESBL)-producing enterobacteriaceae among patients at hospital admission and of subsequent colonization with ESBL-producing enterobacteriaceae among patients during hospitalization. Infect Control Hosp Epidemiol. 2009;30:534–42.PubMedCrossRefGoogle Scholar
  18. 18.
    Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRefGoogle Scholar
  19. 19.
    Clinical and Laboratory Standards Institute (CLSI) 2009. Performance standards for antimicrobial susceptibility testing, 17th informational supplement. CLSI, Wayne, PA; 2008.Google Scholar
  20. 20.
    Peña C, Gudiol C, Tubau F, et al. Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients. Clin Microbiol Infect. 2006;12:279–84.PubMedCrossRefGoogle Scholar
  21. 21.
    Ena J, Arjona F, Martínez-Peinado C, et al. Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Urology. 2006;68:1169–74.PubMedCrossRefGoogle Scholar
  22. 22.
    Lartigue MF, Zinsius C, Wenger A, et al. Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland. Antimicrob Agents Chemother. 2007;51:2855–60.PubMedCrossRefGoogle Scholar
  23. 23.
    Falagas ME, Kastoris AC, Kapaskelis AM, et al. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010;10:43–50.PubMedCrossRefGoogle Scholar
  24. 24.
    Ti TY, Kumarasinghe G, Taylor MB, et al. What is true community-acquired urinary tract infection? Comparison of pathogens identified in urine from routine outpatient specimens and from community clinics in a prospective study. Eur J Clin Microbiol Infect Dis. 2003;22:242–5.PubMedGoogle Scholar
  25. 25.
    Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10:597–602.PubMedCrossRefGoogle Scholar
  26. 26.
    Gupta K, Hooton TM, Naber KG, et al. Executive summary: International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:561–4.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • S. Meier
    • 1
  • R. Weber
    • 1
  • R. Zbinden
    • 2
  • C. Ruef
    • 1
  • B. Hasse
    • 1
    Email author
  1. 1.Division of Infectious Diseases and Hospital EpidemiologyUniversity Hospital Zurich, University of ZurichZurichSwitzerland
  2. 2.Institute of Medical MicrobiologyUniversity of ZurichZurichSwitzerland

Personalised recommendations